Support and Resistance Basics

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top 10 Correlated ETFs

MLND


Top 10 Correlated Stocks

MLND


In the News

04:00 13 Aug 2022 MLND

Tempest and Millendo Announce Stockholder Approval of Merger

Tempest to Trade on Nasdaq Public Markets Under Ticker “TPST” Tempest to Trade on Nasdaq Public Markets Under Ticker “TPST”

07:41 13 Aug 2022 MLND

MILLENDO INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Millendo Therapeutics, Inc. - MLND

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Millendo Therapeutics, Inc. (NasdaqGS: MLND) (“the Company”) with Tempest Therapeutics, Inc. pursuant to which Millendo shareholders are expected to only own approximately 18.5% of the combined company, subject to adjustments. KSF is seeking to determine whether the merger and the process that led to it are

11:39 13 Aug 2022 MLND

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Millendo Therapeutics, Inc. - MLND

NEW YORK, April 2, 2021 /PRNewswire/ --  Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Millendo Therapeutics, Inc. ("MLND" or the "Company") ( MLND ) relating to its proposed merger with Tempest Therapeutics, Inc. Under the terms of the agreement, MLND shareholders are expected to own 18.5% of the combined company. The investigation focuses on whether Millendo Therapeutics, Inc. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.

01:10 13 Aug 2022 MLND

Millendo Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Millendo Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – MLND

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Millendo Therapeutics, Inc. (NASDAQ: MLND) and Tempest Therapeutics, Inc. is fair to Millendo shareholders. Upon completion of the merger, Millendo shareholders are expected to own approximately 18.5% of the combined company while pre-merger Tempest stockholders will own approximately 81.5% of the combined company. Halper Sadeh encourages Millendo shareholders to click here to

08:39 13 Aug 2022 MLND

MLND Stock Price Falls Over 10% Pre-Market: Why It Happened

The stock price of Millendo Therapeutics Inc (NASDAQ: MLND) fell by over 10% pre-market. This is why it happened.

08:37 13 Aug 2022 MLND

Tempest Therapeutics To Go Public Via Millendo Therapeutics Merger

Millendo Therapeutics Inc (NASDAQ: MLND) has agreed to merge with privately-held Tempest Therapeutics Inc in an all-stock transaction. The combined company will operate under the Tempest Therapeutics moniker under ticker 'TPST,' focusing on advancing Tempest's oncology pipeline of small molecule candidates.

06:00 13 Aug 2022 MLND

Millendo Therapeutics (MLND) Investor Presentation - Slideshow

12:30 13 Aug 2022 MLND

Millendo Therapeutics Reports Second Quarter 2020 Operating and Financial Results

Millendo Therapeutics Reports Second Quarter 2020 Operating and Financial Results

12:00 13 Aug 2022 MLND

Millendo Therapeutics Reports Second Quarter 2020 Operating and Financial Results

Millendo Therapeutics Reports Second Quarter 2020 Operating and Financial Results

12:30 13 Aug 2022 MLND

Millendo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

Millendo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

Financial details

Company Rating
Neutral
Market Cap
20.19M
Income
-38.12M
Revenue
0
Book val./share
37.94
Cash/share
53.94
Dividend
-
Dividend %
-
Employees
12
Optionable
No
Shortable
Yes
Earnings
09 Nov 2020
P/E
-0.04
Forward P/E
-
PEG
0.01
P/S
-
P/B
0.03
P/C
0.04
P/FCF
-0.04
Quick Ratio
6.99
Current Ratio
7.2
Debt / Equity
0.03
LT Debt / Equity
0.03
-
-
EPS (TTM)
-30.31
EPS next Y
-
EPS next Q
-
EPS this Y
-40.62%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-45.01%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-15.68%
-
-
-
-
SMA20
-6.49%
SMA50
-35.14%
SMA100
-14.96%
Inst Own
0%
Inst Trans
0%
ROA
-50%
ROE
-88%
ROC
-0.58%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
19.04M
Shs Float
13.65M
-
-
-
-
Target Price
-
52W Range
1.06-41.549793
52W High
-94.44%
52W Low
+128%
RSI
48.23
Rel Volume
0.23
Avg Volume
140.98K
Volume
32.58K
Perf Week
3.64%
Perf Month
-1.3%
Perf Quarter
-29.85%
Perf Half Y
-37.36%
-
-
-
-
Beta
0.476276
-
-
Volatility
0.09%, 0.15%
Prev Close
-0.44%
Price
2.28
Change
4.11%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2020-12-31

Metric History 2016-12-312017-12-312018-12-312019-12-31 2020-12-31
Revenue per share
4.571.86000
Net income per share
-575.72-321.49-263.65-48.77-28.95
Operating cash flow per share
-432.07-287.28-229.28-45.11-24.2
Free cash flow per share
-450.16-288.28-229.63-45.55-24.22
Cash per share
800.58423.84753.0968.3730.36
Book value per share
757.4405.52708.9865.5226.82
Tangible book value per share
757.4405.52708.9865.5226.82
Share holders equity per share
757.4405.52708.9865.5226.82
Interest debt per share
006.853.812.12
Market cap
48.87M38.89M15.86M115.96M37.16M
Enterprise value
4.94M23.18M-56.86M58M1.66M
P/E ratio
-0.59-0.76-0.58-2.6-1.02
Price to sales ratio
74.83131.82000
POCF ratio
-0.79-0.85-0.67-2.81-1.22
PFCF ratio
-0.76-0.85-0.67-2.79-1.22
P/B Ratio
0.450.60.221.941.1
PTB ratio
0.450.60.221.941.1
EV to sales
7.5678.59000
Enterprise value over EBITDA
-0.06-0.472.13-1.31-0.05
EV to operating cash flow
-0.08-0.512.4-1.41-0.05
EV to free cash flow
-0.08-0.512.4-1.39-0.05
Earnings yield
-1.68-1.31-1.71-0.38-0.98
Free cash flow yield
-1.32-1.18-1.49-0.36-0.82
Debt to equity
000.010.040.05
Debt to assets
0.120.120.130.20.22
Net debt to EBITDA
0.550.322.731.311.02
Current ratio
8.828.818.55.685.12
Interest coverage
00-200.5543.740
Income quality
0.750.890.870.920.84
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
33.1462.16000
Intangibles to total assets
00000
Capex to operating cash flow
0.04000.010
Capex to revenue
-3.96-0.54000
Capex to depreciation
-1.16-0.1-1.13-0.38-0.02
Stock based compensation to revenue
14.1123.37000
Graham number
3.13K1.71K2.05K268.14132.18
ROIC
-0.69-0.72-0.36-0.73-1.02
Return on tangible assets
-0.67-0.7-0.32-0.59-0.84
Graham Net
700.32369.89663.8652.922.84
Working capital
103.24M60.98M73.61M58.61M32.91M
Tangible asset value
00000
Net current asset value
102.12M60.23M72.47M56.03M31.22M
Invested capital
000.010.080.08
Average receivables
001.8M1.28M795K
Average payables
1.84M1.87M1.75M1.5M1.49M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
147.531.04K000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
2.470.35000
Inventory turnover
00000
ROE
-0.76-0.79-0.37-0.74-1.08
Capex per share
-18.1-1-0.35-0.43-0.02

Quarterly Fundamentals Overview

Last date of statement is 2021-06-30 for Q2

Metric History 2019-06-302020-03-312020-06-302021-03-31 2021-06-30
Revenue per share
00000
Net income per share
-11.07-9.76-8.43-6.61-5.57
Operating cash flow per share
-11.85-8.26-6.21-9.330
Free cash flow per share
-12.15-8.28-6.21-9.33-0.07
Cash per share
61.9747.1639.7221.4853.94
Book value per share
61.6944.4335.4820.2137.94
Tangible book value per share
61.6944.4335.4820.2137.94
Share holders equity per share
61.6944.4335.4820.2137.94
Interest debt per share
3.953.032.751.943.73
Market cap
168.19M97.41M33.44M22.83M14.18M
Enterprise value
116.75M43.29M-13.39M-1.51M-49.78M
P/E ratio
-4.26-2.03-0.78-0.68-0.5
Price to sales ratio
00000
POCF ratio
-15.91-9.59-4.25-1.930
PFCF ratio
-15.52-9.56-4.25-1.93-168.79
P/B Ratio
3.061.780.740.890.29
PTB ratio
3.061.780.740.890.29
EV to sales
00000
Enterprise value over EBITDA
-11.49-3.651.30.18-7.16
EV to operating cash flow
-11.04-4.261.70.130
EV to free cash flow
-10.77-4.251.70.13592.65
Earnings yield
-0.06-0.12-0.32-0.37-0.5
Free cash flow yield
-0.06-0.1-0.24-0.52-0.01
Debt to equity
0.040.040.050.060.03
Debt to assets
0.190.20.210.190.36
Net debt to EBITDA
5.064.574.542.9-9.2
Current ratio
5.95.765.366.397.2
Interest coverage
32.4674.9100-24.58
Income quality
1.070.850.741.410
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.030000
Capex to revenue
00000
Capex to depreciation
2.1-0.0900-0.51
Stock based compensation to revenue
00000
Graham number
123.9398.7582.0254.8468.92
ROIC
-0.18-0.21-0.23-0.32-0.1
Return on tangible assets
-0.14-0.18-0.19-0.26-0.09
Graham Net
48.8437.230.2216.8632.35
Working capital
53.58M53.41M43.99M24.8M60.7M
Tangible asset value
00000
Net current asset value
51.21M51.22M41.88M23.32M43.11M
Invested capital
0.070.070.080.10.09
Average receivables
1.21M918K255K300K0
Average payables
1.95M1.79M1.08M811K3.75M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.18-0.22-0.24-0.33-0.15
Capex per share
-0.3-0.0200-0.07

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap